Currently, the possibility of using drugs that reduce the activity of HPAA (antagonists of CRH receptors and glucocorticoid receptors, inhibitors of glucocorticoid synthesis) for the treatment of depression is being investigated [184,185]. The gene discussed is NR3C1; the disease is depressive disorder.